Akten is owned by Akorn.
Akten contains Lidocaine Hydrochloride.
Akten has a total of 1 drug patent out of which 0 drug patents have expired.
Akten was authorised for market use on 07 October, 2008.
Akten is available in gel;ophthalmic dosage forms.
Akten can be used as method of inducing topical anesthesia in the eye.
The generics of Akten are possible to be released after 24 July, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8759401||AKORN||Aqueous gel formulation and method for inducing topical anesthesia|| |
(3 years from now)
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic